ArticleRisk management and healthcare policy2025
Impact of Serum Magnesium Levels on Mineral-Bone Metabolism in Non-Dialysis-Dependent Chronic Kidney Disease.
Article in Risk management and healthcare policy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Quantitative sensory testing of pain in osteoporosis: a pilot randomized clinical trial with magnesium supplementation.Aging clinical and experimental research · 2026Trial
- Associations of calcium and magnesium intakes and their intake ratio with albuminuria in middle-aged and older adults.PloS one · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Magnesium is one of the important minerals in the human body. The metabolic imbalance of magnesium has been found in patients with chronic kidney disease (CKD), but the research on the serum magnesium level of patients with non-dialysis-dependent CKD (NDD-CKD) and its relationship with mineral-skeletal metabolic disorder (CKD-MBD) is still relatively limited. This study aims to explore the changes in serum magnesium levels in patients with non-dialysis-dependent CKD at different stages and evaluate its relationship with mineral metabolism markers (calcium, phosphorus, iPTH and alkaline phosphatase). Methods: A retrospective analysis was conducted on data from 156 patients with stage 3-5 CKD (G3-G5) admitted to Handan First Hospital between March 2017 and December 2019. Serum magnesium, calcium, phosphorus, intact parathyroid hormone (iPTH), and alkaline phosphatase (AKP) levels were analyzed. The patients were categorized into hypomagnesemia, normal magnesium, and hypermagnesemia groups based on serum magnesium levels. Correlations between magnesium levels and phosphorus, iPTH, and AKP levels were analyzed. Results: Serum magnesium levels displayed an upward trend across CKD stages G3 to G5, though this trend was not statistically significant. The prevalence of hypomagnesemia was 0%, 6.82%, and 15.07%, while the incidence of hypermagnesemia was 5.13%, 13.64%, and 30.14% in G3, G4, and G5 stages, respectively. Serum magnesium levels demonstrated a significant positive correlation with serum calcium and the calcium-phosphorus product, whereas no correlation was observed with serum phosphorus or iPTH levels. Conclusion: Magnesium metabolic disorders progressively increase with CKD severity, with the highest prevalence observed in stage G5. These findings indicate that changes in serum magnesium levels may influence the development and progression of CKD-MBDs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.